Improvement of clinical outcomes and liver function in cirrhotic patients by selective COX-2 inhibitors:A retrospective study  

作　　者：Zhu Yang Ming Chen Yang Tai Huan Tong Zhiyin Huang Jinhang Gao Chengwei Tang 

机构地区：[1]Department of Gastroenterology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [2]Digestive Disease Institute,West China Clinical College,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2024年第23期2871-2873,共3页中华医学杂志(英文版)

基　　金：supported by grants from the National Natural Science Fundation of China(Nos.82170623,82170625,U1702281,81873584,82000613,and 82000574);the National Key R&D Program of China(No.2017YFA0205404);the“1.3.5”projects for disciplines of excellence of West China Hospital,Sichuan University(No.ZYGD18004).

摘　　要：Liver cirrhosis is associated with high morbidity,mortality,and medical costs worldwide.Although transjugular intrahepatic portosystemic shunt(TIPS)has been shown to improve the survival of patients with cirrhosis,systemic inflammation is critical in the initiation and progression of decompensated cirrhosis.Our previous study showed that celecoxib,a selective cyclooxygenase-2 inhibitor(COX-2-I)with anti-inflammatory efficacy,effectively ameliorated liver fibrosis.[1]However,few studies have clinically explored the treatment of liver cirrhosis with COX-2-I.

关 键 词：PATIENTS CIRRHOSIS MORTALITY 

分 类 号：R73[医药卫生—肿瘤]